3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Gynecologic
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Sarcoma
1
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Temozolomide
102
Radiotherapy
47
Bevacizumab
33
Carboplatin
23
Irinotecan
20
pembrolizumab
17
Radiosurgery
16
Nivolumab
16
Radiation
14
Cyclophosphamide
11
Magnetic Resonance Spectroscopy
10
fludarabine
8
Trastuzumab
8
Radiotherapy, Intensity-Modulated
8
Carmustine
8
Surgical Procedures, Operative
7
Specimen Handling
7
Pemetrexed
7
Paclitaxel
7
Interleukin-2
7
Filgrastim
7
Everolimus
7
Erlotinib Hydrochloride
7
temsirolimus
6
Vorinostat
6
Radiotherapy, Conformal
6
Lomustine
6
Ipilimumab
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Gemcitabine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Interleukin-15
×
CNS
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled